샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794703

세계의 RNA 기반 치료제 시장

RNA-based Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 274 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

RNA 기반 치료제 세계 시장은 2030년까지 56억 달러에 달할 전망

2024년에 42억 달러로 추정되는 RNA 기반 치료제 세계 시장은 2024년부터 2030년까지 CAGR 4.8%로 성장하여 2030년에는 56억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 mRNA 치료제는 CAGR 5.3%를 기록하며 분석 기간 종료시에는 24억 달러에 달할 것으로 예측됩니다. 안티센스 올리고뉴클레오티드 치료제 부문의 성장률은 분석 기간 CAGR로 5.3%로 추정됩니다.

미국 시장은 11억 달러, 중국은 CAGR 8.8%로 성장할 것으로 예측

미국의 RNA 기반 치료제 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.8%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.0%와 3.7%로 예측됩니다. 유럽에서는 독일이 CAGR 2.8%로 성장할 것으로 예측됩니다.

세계의 RNA 기반 치료제 시장 - 주요 동향과 촉진요인 정리

코드에서 치료로: RNA 치료제가 정밀의료의 경계를 어떻게 변화시킬 것인가?

치료제로서 RNA의 출현을 촉진하는 과학적 진보는 무엇인가?

RNA 기반 치료제는 단백질 수준이 아닌 유전자 및 전사체 수준에서 질병 경로를 조절할 수 있는 정밀의료의 새로운 시대를 의미합니다. 메신저 RNA(mRNA), small interfering RNA(siRNA), 안티센스 올리고뉴클레오티드(ASO), RNA 앱타머 등 RNA의 치료제로서의 다양성으로 인해 RNA는 미충족 임상 수요가 높은 질병을 타겟팅하기 위한 가장 유망한 플랫폼 중 하나가 되고 있습니다. 저분자 약물이나 단클론항체와 달리 RNA 기반 치료법은 유전자 발현을 직접 조작할 수 있기 때문에 특정 유전질환, 암, 감염성 질환 등 과거에는 치료가 불가능하다고 여겨졌던 질병에 대한 개입이 가능합니다.

최근 RNA의 안정성, 세포 내 전달 및 화학적 변형에 대한 과학적 혁신은 빠른 분해 및 오프 타겟 효과와 관련된 초기 문제를 많이 해결했습니다. 변형된 뉴클레오시드, 지질나노입자(LNP), 컨쥬게이션 기술을 통해 RNA 약물의 약동학적 프로파일이 크게 개선되어 전신 투여 및 간, 근육, 중추신경계 등의 조직에 표적 전달이 가능해졌습니다. COVID-19 팬데믹 상황에서 mRNA 백신의 성공은 RNA 기반 치료제의 확장성, 안전성, 개발 속도를 입증하며 여러 치료 분야에 걸쳐 파이프라인이 폭발적으로 증가했습니다.

또한, CRISPR-Cas13, 스플라이스 변형 올리고뉴클레오티드, 고리형 RNA 등의 RNA 편집 및 변형 도구는 유전자 녹다운이나 단백질 발현을 넘어 새로운 치료 전략을 가능하게 하고 있습니다. 이러한 접근법은 우성 음성 돌연변이 치료, 스플라이싱 결함 교정, 또는 유전체를 영구적으로 변경하지 않고도 안정적인 단백질 발현을 생성할 수 있는 가능성을 열어주며, 유전자 편집에 비해 더 안전하고 가역적인 옵션을 제공합니다.

채택이 가속화되고 임상 파이프라인이 확대되고 있는 치료 분야는?

RNA 기반 치료제는 다양한 치료 영역으로 빠르게 확대되고 있으며, 초기 승인 및 후기 파이프라인은 희귀 유전질환, 종양학, 심대사질환, 감염질환에 집중되어 있습니다. 희귀질환 분야에서는 스핀라자(Spinraza, 누시넬센)와 졸겐스마(Zolgensma)와 같은 약물이 척수성 근위축증을 표적으로 하는 ASO 및 유전자 치료의 길을 열었고, 온파트로(Onpattro, 패티실란)와 기블라리(Givlaari, 디보실란)와 같은 siRNA 기반 치료제가 각각 트랜스시레틴아밀로이드증과 급성 간 포르피린증 치료에서 임상적 효과를 입증하고 있습니다.

암 분야 파이프라인은 점점 더 견고해지고 있으며, mRNA 기반 암 백신, 면역조절제, 신항원 표적 치료제가 초기 및 중기 임상시험에 진입하고 있습니다. 이러한 RNA 치료제는 항원 특이적 면역반응을 자극하고, 종양의 미세환경을 교정하거나 발암 유발인자를 침묵시키는 것을 목표로 합니다. 종양 특이적 돌연변이 프로파일을 이용하여 맞춤형 mRNA 페이로드를 생성하는 맞춤형 암 백신은 특히 체크포인트 억제제와 병용할 경우 유망한 면역원성을 보이고 있습니다.

RNA 간섭이나 ASO는 콜레스테롤, 중성지방, 지단백질 수치를 조절하는 데 사용되고 있습니다. PCSK9을 표적으로 하는 siRNA인 Inclisiran은 연 2회 투여로 LDL 콜레스테롤을 감소시켜 단클론항체를 대체할 수 있는 순응도 높은 치료옵션을 제공합니다. 마찬가지로 비만, 비알코올성 지방간염(NASH), 제2형 당뇨병을 치료하기 위한 RNA 기반 접근법도 특히 조직 표적화 가능성과 이전에는 접근하기 어려웠던 세포 내 단백질을 조절하는 능력으로 인해 활발히 연구되고 있습니다.

감염병 분야에서는 COVID-19 외에도 RNA 플랫폼이 독감, RSV, CMV, HIV, 심지어 말라리아 백신에도 적용되고 있습니다. RNA 치료제는 신속한 설계 유연성과 복잡한 항원을 코딩할 수 있는 능력으로 인해 전염병 대응 및 발병 대응 프레임워크에서 중요한 도구로 자리매김하고 있습니다.

배달 기술과 규제 프레임워크는 시장의 가능성을 어떻게 형성하고 있는가?

RNA 치료제에서 전달은 여전히 가장 중요한 기술적 장벽이자 기술 혁신의 영역입니다. 효과적이고 조직 특이적인 전달 시스템은 치료 지표뿐만 아니라 안전성, 투여 횟수, 비용도 결정합니다. 가장 잘 알려진 전달 수단인 지질 나노입자는 새로운 이온화 가능한 지질, 생분해성 캐리어, 표적성을 높이고 독성을 줄이기 위한 표면 개질을 통해 최적화되고 있습니다. LNP는 간세포 전달에 특히 효과적이지만, 근육, 폐, 중추신경계 등 다른 조직에는 GalNAc 컨쥬게이트, 엑소좀, 폴리머 기반 시스템 등 특수한 비히클이 필요합니다.

핵산의 안정성과 면역원성은 2′:-O-메틸 및 포스포로티오에이트 결합과 같은 화학적 변형을 통해 뉴클레아제 내성을 향상시키고 자연면역의 활성화를 억제하는 방식으로 해결하고 있습니다. 특히 단백질 대체 요법을 위해 단백질의 장시간 안정된 발현을 달성하기 위해 자유 말단이 없는 고리형 RNA 구조물도 개발되고 있습니다.

규제 측면에서 미국 FDA 및 EMA와 같은 기관은 RNA 기반 의약품의 개발 및 승인을 가속화하기 위해 신속한 경로 및 지침 프레임 워크를 구축했습니다. COVID-19 사태로 인해 RNA 백신의 승인 속도가 빨라지면서 규제 당국은 RNA 플랫폼에 대한 이해도가 높아졌고, 심사 가속화, 희귀질환 치료제 지정, 획기적 치료제로 지정되는 등 다양한 혜택을 누리고 있습니다. 그러나 기술의 규모가 확대됨에 따라 면역원성, 생체 내 분포, 제조 일관성에 대한 안전성 우려로 인해 엄격한 시판 후 조사와 견고한 CMC(화학, 제조, 관리) 프레임워크가 필요하게 되었습니다.

RNA 기반 치료제 시장의 장기적인 성장 동력은?

RNA 기반 치료제 시장 성장의 원동력은 기술적 성숙, 임상적 성공, 바이오의약품의 가치사슬 전반에 걸친 투자 증가에 따른 것입니다. 핵심 성장 요인 중 하나는 RNA 고유의 프로그램 가능성입니다. 기존 바이오의약품과 달리 RNA 치료제는 뉴클레오티드 서열을 변경하여 신속하게 재설계할 수 있기 때문에 전달 시스템과 백본이 적응증 간에 재사용되는 플랫폼 기반 개발 모델을 통해 탐색 기간과 연구개발 비용을 획기적으로 줄일 수 있습니다.

RNA 백신과 유전자 침묵 약물의 성공은 생명공학 스타트업, 대형 제약사, 계약 생산업체에 대한 투자를 촉진했습니다. 대형 제약사들은 파이프라인 역량을 확대하기 위해 RNA 전문 바이오텍 기업들과 전략적 제휴를 맺거나 인수하고 있습니다. 또한, 합성생물학, RNA 프린팅, 모듈형 LNP 라이브러리의 개선으로 제조의 확장성과 비용 효율성이 향상되어 보다 광범위한 상업적 배포가 가능해졌습니다.

특히 새로운 전달 시스템을 통해 투여 빈도와 침습성이 감소함에 따라 환자와 의사의 수용성도 높아지고 있습니다. 예를 들어, GalNAc를 결합시킨 siRNA는 6개월에 한 번씩 피하투여가 가능하여 만성질환 관리의 순응도를 높일 수 있습니다. 또한, 맞춤형 mRNA 암 백신과 다가성 감염 백신은 헬스케어 산업의 정밀화, 예방 및 개인화로의 전환과 일치하는 유망성을 가지고 있습니다.

마지막으로, 장쇄 비암호화 RNA, 마이크로 RNA, RNA 편집에 이르기까지 RNA 생물학에 대한 이해의 확장은 새로운 표적과 메커니즘의 지속적인 파이프라인을 보장하고 있습니다. RNA 치료제가 틈새치료제에서 다양한 질환에 대한 주류 치료제로 진화함에 따라, 기술 혁신, 규제, 수요의 수렴으로 21세기 의료의 중심축으로 자리매김할 것으로 보입니다.

부문

유형(mRNA 치료제, 안티센스·올리고뉴클레오티드 치료제, RNA 간섭 치료제, 기타 치료제 유형), 투여 경로(정맥내 루트, 피하 루트, 근육내 루트)

조사 대상 기업 사례

  • ADARx Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech SE
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dicerna Pharmaceuticals
  • Entos Pharmaceuticals Inc.
  • GlaxoSmithKline plc(GSK)
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics plc
  • Sirnaomics, Inc.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM

Global RNA-based Therapeutics Market to Reach US$5.6 Billion by 2030

The global market for RNA-based Therapeutics estimated at US$4.2 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. mRNA Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Antisense Oligonucleotide Therapeutics segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 8.8% CAGR

The RNA-based Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global RNA-Based Therapeutics Market - Key Trends & Drivers Summarized

From Code to Cure: How RNA Therapeutics Are Transforming the Precision Medicine Frontier

What Scientific Advances Are Catalyzing the Emergence of RNA as a Therapeutic Modality?

RNA-based therapeutics represent a new era in precision medicine, where disease pathways can be modulated at the genetic and transcriptomic level rather than the protein level. The versatility of RNA as a therapeutic class-encompassing messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and RNA aptamers-has made it one of the most promising platforms for targeting diseases with high unmet clinical needs. Unlike small-molecule drugs or monoclonal antibodies, RNA-based modalities enable direct manipulation of gene expression, offering interventions for diseases once considered undruggable, including certain genetic disorders, cancers, and infectious diseases.

Recent scientific breakthroughs in RNA stability, intracellular delivery, and chemical modification have resolved many of the early challenges associated with rapid degradation and off-target effects. Modified nucleosides, lipid nanoparticles (LNPs), and conjugation techniques have significantly improved the pharmacokinetic profiles of RNA drugs, allowing for systemic administration and targeted delivery to tissues such as the liver, muscle, or even the central nervous system. The success of mRNA vaccines during the COVID-19 pandemic validated the scalability, safety, and speed of development of RNA-based modalities, triggering a pipeline explosion across multiple therapeutic areas.

Moreover, RNA editing and modulation tools-such as CRISPR-Cas13, splice-modifying oligonucleotides, and circular RNA-are enabling new therapeutic strategies beyond gene knockdown or protein expression. These approaches open the door to treating dominant-negative mutations, correcting splicing defects, or generating stable protein expression without permanent genomic changes, offering safer and more reversible options compared to gene editing.

Which Therapeutic Areas Are Seeing Accelerated Adoption and Clinical Pipeline Expansion?

RNA-based therapies are rapidly expanding into diverse therapeutic domains, with early approvals and late-stage pipelines concentrated in rare genetic disorders, oncology, cardiometabolic diseases, and infectious diseases. In the rare disease space, drugs like Spinraza (nusinersen) and Zolgensma have paved the way for ASO and gene therapies targeting spinal muscular atrophy, while siRNA-based treatments like Onpattro (patisiran) and Givlaari (givosiran) have demonstrated clinical efficacy in treating transthyretin amyloidosis and acute hepatic porphyria, respectively.

The oncology pipeline is becoming increasingly robust, with mRNA-based cancer vaccines, immune modulators, and neoantigen-targeted therapeutics entering early and mid-stage clinical trials. These RNA therapeutics aim to stimulate antigen-specific immune responses, modify tumor microenvironments, or silence oncogenic drivers. Personalized cancer vaccines using tumor-specific mutation profiles to create individualized mRNA payloads are showing promising immunogenicity, especially when combined with checkpoint inhibitors.

Cardiometabolic diseases are another growth frontier, where RNA interference and ASOs are being used to modulate cholesterol, triglyceride, and lipoprotein levels. Inclisiran, an siRNA targeting PCSK9, has demonstrated LDL cholesterol reduction with biannual dosing, offering a compliance-friendly alternative to monoclonal antibodies. Similarly, RNA-based approaches to treat obesity, nonalcoholic steatohepatitis (NASH), and type 2 diabetes are under active exploration, particularly due to their tissue-targeting potential and ability to modulate previously inaccessible intracellular proteins.

In infectious diseases, beyond COVID-19, RNA platforms are being adapted for vaccines against influenza, RSV, CMV, HIV, and even malaria. Their rapid design flexibility and ability to encode complex antigens position RNA therapeutics as a valuable tool in pandemic preparedness and outbreak response frameworks.

How Are Delivery Technologies and Regulatory Frameworks Shaping Market Viability?

Delivery remains the most critical technical barrier and innovation area in RNA therapeutics. Effective, tissue-specific delivery systems determine not only the therapeutic index but also safety, dosing frequency, and cost. Lipid nanoparticles, the most established delivery vehicle, are being optimized with novel ionizable lipids, biodegradable carriers, and surface modifications to enhance targeting and reduce toxicity. LNPs are particularly effective in hepatocyte delivery, but other tissues-such as muscle, lungs, and CNS-require specialized vehicles like GalNAc conjugates, exosomes, or polymer-based systems.

Nucleic acid stability and immunogenicity are being addressed through chemical modifications such as 2′-O-methyl and phosphorothioate linkages, which improve nuclease resistance and reduce innate immune activation. Circular RNA constructs, which lack free ends, are also being developed to achieve prolonged and more stable protein expression, especially for protein replacement therapies.

From a regulatory perspective, agencies like the U.S. FDA and EMA have established expedited pathways and guidance frameworks to accelerate the development and approval of RNA-based drugs. The accelerated approval of RNA vaccines during the pandemic has enhanced regulator familiarity with RNA platforms, leading to faster reviews, orphan designations, and breakthrough therapy labels. However, as the technology scales, safety concerns around immunogenicity, biodistribution, and manufacturing consistency will require stringent post-marketing surveillance and robust CMC (chemistry, manufacturing, and controls) frameworks.

What’s Driving Long-Term Growth in the RNA-Based Therapeutics Market?

The growth in the RNA-based therapeutics market is driven by technological maturity, clinical success, and increased investment across the biopharmaceutical value chain. One of the core growth drivers is the inherent programmability of RNA. Unlike traditional biologics, RNA therapeutics can be rapidly redesigned by altering nucleotide sequences, allowing platform-based development models where delivery systems and backbones are reused across indications, dramatically reducing discovery timelines and R&D costs.

The success of RNA vaccines and gene silencing drugs has catalyzed investment across biotech startups, large pharma, and contract manufacturers. Big pharma companies are entering strategic collaborations or acquiring RNA-focused biotech firms to expand their pipeline capabilities. Additionally, improvements in synthetic biology, RNA printing, and modular LNP libraries are making manufacturing more scalable and cost-efficient, enabling a broader commercial rollout.

Patient and physician acceptance is also growing, particularly as newer delivery systems reduce the frequency and invasiveness of administration. For example, siRNAs with GalNAc conjugation offer subcutaneous dosing with semi-annual administration, enhancing compliance in chronic disease management. Moreover, the promise of individualized mRNA cancer vaccines and multi-valent infectious disease vaccines is aligning with the healthcare industry's shift toward precision, prevention, and personalization.

Finally, the expanding understanding of RNA biology-spanning long non-coding RNAs, microRNAs, and RNA editing-ensures a continuous pipeline of new targets and mechanisms. As RNA therapeutics evolve from niche treatments to mainstream interventions across diverse diseases, the convergence of innovation, regulation, and demand will solidify their position as a central pillar of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the RNA-based Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics, Other Therapeutic Types); Administration Route (Intravenous Route, Subcutaneous Route, Intramuscular Route)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • ADARx Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech SE
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dicerna Pharmaceuticals
  • Entos Pharmaceuticals Inc.
  • GlaxoSmithKline plc (GSK)
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics plc
  • Sirnaomics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • RNA-based Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthrough Success of mRNA Vaccines Throws the Spotlight on RNA-Based Drug Platforms
    • Expansion of Gene Silencing and Modulation Techniques Drives Therapeutic Innovation
    • Increased Investment in RNA Therapeutics Startups Fuels Clinical Pipeline Acceleration
    • Advancements in Lipid Nanoparticle and Carrier Systems Enhance Targeted RNA Delivery
    • Rising Incidence of Genetic and Rare Diseases Strengthens Demand for RNA Precision Therapies
    • Expansion of mRNA and siRNA Modalities Creates New Treatment Pathways for Chronic Diseases
    • Regulatory Fast-Track Designations Propel Commercial Viability of RNA Candidates
    • Emerging Applications in Oncology and Immunotherapy Sustain Long-Term Market Growth
    • Strategic Collaborations Between Pharma and Biotech Firms Expand Technology Access
    • Intellectual Property Portfolios in RNA Editing and Splicing Mechanisms Drive Competitive Differentiation
    • Growing Adoption of RNA Screening in Drug Discovery Enhances Preclinical Development
    • Rising Public and Private Funding for RNA Research Accelerates Platform Maturity
    • Focus on Personalized Medicine and Rare Disease Therapies Expands Commercial Opportunity
    • Automation and Digitization Trends Streamline RNA Manufacturing and Scalability
    • Improvements in Thermostability and Storage Conditions Drive Broader Distribution
    • Growth in Companion Diagnostics Enhances Target Selection for RNA-Based Treatments
    • Expansion in RNA-Based Prophylactics for Infectious Diseases Propels Preventive Healthcare Adoption
    • Positive Regulatory Outcomes in RNAi Therapies Strengthen Confidence in Market Pathways
    • Integration of AI in RNA Sequence Optimization Enhances Candidate Screening and Targeting
    • Globalization of Clinical Trials Enables Rapid Market Access for RNA-Based Innovations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNA-based Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNA-based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for RNA-based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for mRNA Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antisense Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antisense Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antisense Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for RNA Interference Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for RNA Interference Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for RNA Interference Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutic Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapeutic Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapeutic Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Intravenous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Subcutaneous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Subcutaneous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Subcutaneous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Intramuscular Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Intramuscular Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Intramuscular Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • JAPAN
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • CHINA
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • EUROPE
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for RNA-based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for RNA-based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • FRANCE
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • GERMANY
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for RNA-based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for RNA-based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • INDIA
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for RNA-based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for RNA-based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for RNA-based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for RNA-based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030
  • AFRICA
    • RNA-based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for RNA-based Therapeutics by Type - mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for RNA-based Therapeutics by Type - Percentage Breakdown of Value Sales for mRNA Therapeutics, Antisense Oligonucleotide Therapeutics, RNA Interference Therapeutics and Other Therapeutic Types for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for RNA-based Therapeutics by Administration Route - Intravenous Route, Subcutaneous Route and Intramuscular Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for RNA-based Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route, Subcutaneous Route and Intramuscular Route for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제